Free Sierra Leone: Zyprexa

See also: Generic Zyprexa Relprevv, Generic Zyprexa Zydis

Zyprexa is a brand name of olanzapine, approved by the FDA in the following formulation(s):

ZYPREXA (olanzapine - injectable; intramuscular)

Manufacturer: LILLY

Approval date: March 29, 2004

Strength(s): 10MG/VIAL ^[RLD]^[AP]

ZYPREXA (olanzapine - tablet; oral)

Manufacturer: LILLY

Approval date: September 30, 1996

Strength(s): 10MG ^[AB], 2.5MG ^[AB], 5MG ^[RLD]^[AB], 7.5MG ^[AB]

Manufacturer: LILLY

Approval date: September 9, 1997

Strength(s): 15MG ^[AB], 20MG ^[AB]

Has a generic version of Zyprexa been approved?

A generic version of Zyprexa has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zyprexa and have been approved by the FDA:

olanzapine injectable; intramuscular

Manufacturer: INNOPHARMA LLC

Approval date: October 24, 2011

Strength(s): 10MG/VIAL ^[AP]

olanzapine tablet; oral

Manufacturer: DR REDDYS LABS LTD

Approval date: October 24, 2011

Strength(s): 20MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: October 24, 2011

Strength(s): 10MG ^[AB], 15MG ^[AB], 2.5MG ^[AB], 5MG ^[AB], 7.5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyprexa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

2-methyl-thieno-benzodiazepine
Patent 5,229,382
Issued: July 20, 1993
Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Lilly Industries Limited
2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

2-methyl-thieno-benzodiazepine
Patent 5,605,897
Issued: February 25, 1997
Inventor(s): Beasley, Jr.; Charles M. & Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Eli Lilly and Company
Lilly Industries Limited
Olanzapine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- February 25, 2014
  ✓
  Patent use: METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
- August 25, 2014
  ✓
  Pediatric exclusivity

2-methyl-thieno-benzodiazepine
Patent 5,627,178
Issued: May 6, 1997
Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Lilly Industries Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Olanzapine polymorph crystal form
Patent 5,736,541
Issued: April 7, 1998
Inventor(s): Bunnell; Charles Arthur & Hendriksen; Barry Arnold & Larsen; Samuel Dean
Assignee(s): Eli Lilly and Company
Eli Lilly and Company
The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.
Patent expiration dates:
- March 24, 2015
  ✓
  Patent use: CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
- September 24, 2015
  ✓
  Pediatric exclusivity

Methods of treatment using a thieno-benzodiazepine
Patent 5,817,655
Issued: October 6, 1998
Inventor(s): Chakrabarti; Jiban Kumar & Hotten; Terrence Micharl & Tupper; David Edward
Assignee(s): Eli Lilly and Company
Eli Lilly and Company Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno -›2,3-b!›1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Mental disorders
Patent 5,817,656
Issued: October 6, 1998
Inventor(s): Beasley, Jr.; Charles M. & Chakrabarti; Jiban Kumar & Hotten; Terrence Michael & Tupper; David Edward
Assignee(s): Eli Lilly and Company
Eli Lilly and Company Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-›2,3-b!›1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Psychoactive substance disorders
Patent 5,817,657
Issued: October 6, 1998
Inventor(s): Beasley, Jr.; Charles M. & Chakrabarti; Jiban Kumar & Hotten; Terrence Michael & Tupper; David Edward
Assignee(s): Eli Lilly and Company
Eli Lilly and Company Limited
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-›2,3-b!›1,5!benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders relating to the use of psychoactive substances. The compound has the following structure: ##STR1##
Patent expiration dates:
- October 23, 2011
  ✓
  Pediatric exclusivity

Oral 2-methyl-thieno-benzodiazepine formulation
Patent 5,919,485
Issued: July 6, 1999
Inventor(s): Cochran; George Randall & Morris; Tommy Clifford
Assignee(s): Eli Lilly and Company
The invention provides a pharmaceutically acceptable solid oral formulation of olanzapine and a process for making such formulation.
Patent expiration dates:
- March 24, 2015
  ✓
  Patent use: CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
- September 24, 2015
  ✓
  Pediatric exclusivity

Olanzapine dihydrate D
Patent 6,251,895
Issued: June 26, 2001
Inventor(s): Larsen; Samuel Dean & Nichols; John Richard & Reutzel; Susan Marie & Stephenson; Gregory Alan
Assignee(s): Eli Lilly and Company
The present invention provides the novel Dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefor.
Patent expiration dates:
- September 23, 2017
- March 23, 2018
  ✓
  Pediatric exclusivity

Combination therapy for treatment of refractory depression
Patent 6,960,577
Issued: November 1, 2005
Inventor(s): Tollefson; Gary Dennis
Assignee(s): Eli Lilly and Company
Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
Patent expiration dates:
- November 1, 2017
  ✓
  Patent use: PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- March 19, 2012 - TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- December 4, 2012 - NEW PATIENT POPULATION
- June 4, 2013 - PEDIATRIC EXCLUSIVITY

Free Sierra Leone

Thursday, September 22, 2016

Zyprexa